Plastic and Reconstructive Surgery, Global Open (Aug 2024)

Evolving Role of Exosomes in Plastic and Reconstructive Surgery and Dermatology

  • Ian T. McGraw, MD,
  • Erin Elise Wilson, BS,
  • Atta Behfar, MD, PhD,
  • Christopher R. Paradise, PhD,
  • Rod J. Rohrich, MD,
  • Saranya P. Wyles, MD, PhD

DOI
https://doi.org/10.1097/GOX.0000000000006061
Journal volume & issue
Vol. 12, no. 8
p. e6061

Abstract

Read online

Summary:. Exosomes, or extracellular vesicles, represent the latest cell-free addition to the regenerative medicine toolkit. In vitro preclinical studies have demonstrated the safety and efficacy of exosomes, which vary based on source and biomanufacturing, for a myriad of potential therapeutic applications relevant to skin and soft tissue reconstruction. Primary search was performed in September 2021 on the MEDLINE database via PubMed and Ovid, with focus on articles about therapeutic application of exosomes or extracellular vesicles. In total, 130 articles met criteria for applicability, including early-stage clinical trials, preclinical research studies with in vivo application, and articles applicable to plastic and reconstructive surgery and dermatology. Most studies used animal models of human disease processes, using either animal donor cells to isolate exosomes, or human donor cells in animal models. Exosome technology has catapulted as an acellular therapeutic vehicle with off-the-shelf accessibility. These features eliminate prior threshold for broad adoption of regenerative cell-based therapies into surgical and medical practice. To date, there are no exosome products approved by the US Food and Drug Administration. This review highlights exosomes as the new frontier in regenerative medicine and outlines its preclinical therapeutic applications for cutaneous repair and restoration.